BeOne Newsroom
Media Resources
Corporate Press Kits
Review resources about BeOne, formerly BeiGene.
Product & Pipeline Media Resources
Find information about our approved medicines and pipeline molecules.
Media Library
View and download images of our leaders, facilities, company logo and other corporate assets.
Press Releases
Read our latest news.
-
June 12, 2025
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 — Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and…
-
June 11, 2025
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications — New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options…
-
June 11, 2025
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that…
-
June 2, 2025
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 — Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor Data underscore strength of…
-
May 31, 2025
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025 — BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D,…
-
May 27, 2025
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology — BeOne well-positioned to deliver transformative treatments to patients worldwide with powerful oncology portfolio, pioneering clinical development approach, and expanded global…
-
May 27, 2025
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer — Positive opinion for TEVIMBRA in combination with chemotherapy as a first-line treatment of nasopharyngeal cancer (NPC) based on results of…
-
May 22, 2025
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors — New data from SEQUOIA, to be reported in two oral presentations, underscore the benefits of BRUKINSA® as first-line treatment for…
-
May 14, 2025
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation — Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignancies Four oral presentations highlight updated data…
-
May 13, 2025
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its…
-
April 29, 2025
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change…
-
April 17, 2025
BeiGene to Announce First Quarter 2025 Financial Results on May 7 — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change…
Congress Hub
Review the latest information about the data we’re presenting and where you can find us.
Responsible Business & Sustainability Report
Responsible Business & Sustainability is at the core of everything we do to positively impact the lives of patients and society.
Explore More
Our Pipeline
Our broad and deep cancer pipeline is one of the largest in the industry.